Pemvidutide Clinical Trials (2026): 4 Studies for Alcohol Liver Disease & Alcohol Use Disorder (AUD)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 Pemvidutide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Alcohol Liver Disease & Alcohol Use Disorder (AUD)) and 452 total planned enrollment. 1 Pemvidutide clinical trial is actively recruiting at 8 U.S. sites across 5 states. Most recent activity: NCT07009860 (Aug 2027).
Where to Participate: All Pemvidutide Trial Sites in the U.S. (8 sites across 5 states)
Every actively recruiting Pemvidutidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AR | Altimmune Clinical Study Site | North Little Rock72117 | NCT07009860 | Map |
| FL | Altimmune Clinical Study Site | Doral33122 | NCT07009860 | Map |
| FL | Altimmune Clinical Study Site | Miami33125 | NCT07009860 | Map |
| MO | Altimmune Clinical Study Site | St Louis63123 | NCT07009860 | Map |
| NY | Altimmune Clinical Study Site | New York10032 | NCT07009860 | Map |
| NY | Altimmune Clinical Study Site | Syracuse13210 | NCT07009860 | Map |
| TX | Altimmune Clinical Study Site | San Antonio78215 | NCT07009860 | Map |
| TX | Altimmune Clinical Study Site | San Antonio78251 | NCT07009860 | Map |
Pemvidutide clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 1 | 1 | 1 | 3 |
Recruiting Pemvidutide clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07009860 | ALDRESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | P2 | Alcohol Liver Disease | 100 | Jun 2025 |
Pemvidutide clinical trials by indication
Alcohol Liver Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07009860 | ALD | P2 | recruiting | RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) |
Alcohol Use Disorder (AUD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06987513 | AUD | P2 | active not recruiting | RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight |
Non-Alcoholic Steatohepatitis (NASH) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05989711 | IMPACT | P2 | completed | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) |
NASH - Nonalcoholic Steatohepatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04972396 | ALT-801 | P1 | completed | Pemvidutide (ALT-801) DDI Study in Healthy Volunteers |
Pemvidutide pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ALD | NCT07009860 | P2 | recruiting | Alcohol Liver Disease | 100 | — |
| AUD | NCT06987513 | P2 | active not recruiting | Alcohol Use Disorder (AUD) | 100 | — |
| IMPACT | NCT05989711 | P2 | completed | Non-Alcoholic Steatohepatitis (NASH) | 212 | — |
All Pemvidutide trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07009860 | ALD | RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | P2 | recruiting | 100 | Altimmune, Inc. | Jun 2025 |
| NCT06987513 | AUD | RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight | P2 | active not recruiting | 100 | Altimmune, Inc. | May 2025 |
| NCT05989711 | IMPACT | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | P2 | completed | 212 | Altimmune, Inc. | Jul 2023 |
| NCT04972396 | ALT-801 | Pemvidutide (ALT-801) DDI Study in Healthy Volunteers | P1 | completed | 40 | Altimmune, Inc. | Sep 2021 |
Pemvidutide clinical trials: frequently asked questions
- How many Pemvidutide clinical trials are there?
- 4 Pemvidutide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 2 are marked completed.
- Are Pemvidutide clinical trials recruiting in 2026?
- Yes — 1 Pemvidutide trial is actively recruiting in 2026, with 8 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Pemvidutide being studied for?
- Pemvidutide is being studied for Alcohol Liver Disease, Alcohol Use Disorder (AUD), NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Steatohepatitis (NASH). The trials are grouped by indication on this page.
- What phase is Pemvidutide in?
- Pemvidutide clinical trials span 3 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Pemvidutide clinical trials?
- The lead sponsor across the most Pemvidutide trials is Altimmune, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pemvidutideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: